Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014. Vertex reported total third quarter 2014 GAAP revenues of $179 million, including revenues of $127 million from KALYDECO® (ivacaftor). The GAAP net loss for the third quarter of 2014 was $(170) million, or $(0.72) per share, which includes net charges of $84 million.
Help employers find you! Check out all the jobs and post your resume.
